ArticlePloS one2011
Camphene, a plant-derived monoterpene, reduces plasma cholesterol and triglycerides in hyperlipidemic rats independently of HMG-CoA reductase activity.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 107 citations in OpenAlex.
- Evaluation of the Effect of Pistacia atlantica Oleoresin on Blood Sugar, Pressure and Lipids in Patients With Type 2 Diabetes: A Single-Blind, Placebo-Controlled Trial.Endocrinology, diabetes & metabolism · 2024Trial
- Mechanistic Insights into Houttuynia cordata Thunb. as a Potential Therapeutic Strategy Targeting Metabolic Disorders in Preclinical Models.Current nutrition reports · 2026Review
- Article
- Chemical Analysis and Antioxidant Activities of Resin Fractions fromMolecules (Basel, Switzerland) · 2025Article
- Achillea millefolium capsule improved liver enzymes and lipid profile compared to placebo in patients with type 2 diabetes: a double-blind randomized clinical trial.BMC nutrition · 2025Article
- Antimicrobial Properties and Therapeutic Potential of Bioactive Compounds inMolecules (Basel, Switzerland) · 2024Review
- Review
- Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients.Non-coding RNA · 2024Article
- Plant In Vitro Cultures ofMolecules (Basel, Switzerland) · 2024Article
- A Comparison between BulgarianMolecules (Basel, Switzerland) · 2024Article
- Camphene as a Protective Agent in Myocardial Ischemia/Reperfusion Injury.Antioxidants (Basel, Switzerland) · 2024Article
- Article
- Comparative Studies on the Anti-Inflammatory and Apoptotic Activities of Four Greek Essential Oils: Involvement in the Regulation of NF-κΒ and Steroid Receptor Signaling.Life (Basel, Switzerland) · 2023Article
- Regulation of Energy Metabolism and Anti-Inflammatory Activities of Mastiha Fractions fromFoods (Basel, Switzerland) · 2023Article
- Volatile Compounds in Norway Spruce (Plants (Basel, Switzerland) · 2023Article
- Chemical Composition of Atmospheric Air in Nemoral Scots Pine Forests and Submountainous Beech Forests: The Potential Region for the Introduction of Forest Therapy.International journal of environmental research and public health · 2022Article
- Effects of Chios mastic gum on cardiometabolic risk factors.World journal of diabetes · 2022Review
- Analysis of Components and Properties of Extractives fromMolecules (Basel, Switzerland) · 2022Article
- Article
- Phytochemical Screening, Antioxidant and Antibacterial Properties of Extracts ofPlants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCentral to the pathology of coronary heart disease is the accumulation of lipids, cholesterol and triglycerides, within the intima of arterial blood vessels. The search for drugs to treat dislipidemia, remains a major pharmaceutical focus. In this study, we evaluated the hypolipidemic properties of the essential oil from Chios mastic gum (MGO). METHODOLOGY/PRINCIPAL
findingsThe hypolipidemic effect of MGO was investigated in naïve as well as in rats susceptible to detergent-induced hyperlipidemia. Serum cholesterol and triglycerides were determined using commercial kits. HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase activity was measured in HepG2 cell extracts using a radioactive assay; cellular cholesterol and cholesterol esters were assessed using gas chromatography. MGO administration into naïve rats resulted in a dose-dependent reduction in the constitutive synthesis of serum cholesterol and triglycerides. In hyperlipidemic rats, MGO treatment had also a strong hypolipidemic effect. By testing various components of MGO, we show for the first time that the hypolipidemic action is associated with camphene. Administration of camphene at a dose of 30 µg/gr of body weight in hyperlipidemic rats resulted in a 54.5% reduction of total cholesterol (p<0.001), 54% of Low Density Lipoprotein (LDL)-cholesterol (p<0.001) and 34.5% of triglycerides (p<0.001). Treatment of HepG2 cells with camphene led to a decrease in cellular cholesterol content to the same extend as mevinolin, a known HMG-CoA reductase inhibitor. The hypolipidemic action of camphene is independent of HMG-CoA reductase activity, suggesting that its hypocholesterolemic and hypotriglyceridemic effects are associated with a mechanism of action different than that of statins.
conclusionsGiven the critical role that the control of hyperlipidemia plays in cardiovascular disease, the results of our study provide insights into the use of camphene as an alternative lipid lowering agent and merits further evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.